WO2004108747A3 - Lektin-konjugate - Google Patents

Lektin-konjugate Download PDF

Info

Publication number
WO2004108747A3
WO2004108747A3 PCT/EP2004/006141 EP2004006141W WO2004108747A3 WO 2004108747 A3 WO2004108747 A3 WO 2004108747A3 EP 2004006141 W EP2004006141 W EP 2004006141W WO 2004108747 A3 WO2004108747 A3 WO 2004108747A3
Authority
WO
WIPO (PCT)
Prior art keywords
unit
lectin
target
seeking
effector
Prior art date
Application number
PCT/EP2004/006141
Other languages
English (en)
French (fr)
Other versions
WO2004108747A2 (de
Inventor
Bernhard Keppler
Paul Debbage
Wolfgang Buchberger
Original Assignee
Faustus Forschungs Cie
Bernhard Keppler
Paul Debbage
Wolfgang Buchberger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faustus Forschungs Cie, Bernhard Keppler, Paul Debbage, Wolfgang Buchberger filed Critical Faustus Forschungs Cie
Priority to EP04739672A priority Critical patent/EP1635879A2/de
Priority to JP2006508288A priority patent/JP2006527182A/ja
Publication of WO2004108747A2 publication Critical patent/WO2004108747A2/de
Publication of WO2004108747A3 publication Critical patent/WO2004108747A3/de
Priority to US11/294,963 priority patent/US20060251580A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die Erfindung betrifft ein Konjugat, das mindestens eine zielsuchende Einheit, die spezifisch an Rezeptoren auf der Oberfläche von Endothelzellen bindet, und mindestens eine daran über einen Linker gekoppelte Effektoreinheit umfasst, wobei die Effektoreinheit mindestens eine Signaleinheit sowie gegebenenfalls mindestens einen therapeutischen Wirkstoff aufweist und, die zielsuchende Einheit ein Lektin oder ein Fragment oder Derivat davon umfasst, wobei das Lektin kein L-Selektin ist, und die Signaleinheit ein Lanthanidenion umfasst.
PCT/EP2004/006141 2003-06-06 2004-06-07 Lektin-konjugate WO2004108747A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04739672A EP1635879A2 (de) 2003-06-06 2004-06-07 Lektin-konjugate
JP2006508288A JP2006527182A (ja) 2003-06-06 2004-06-07 レクチン結合体
US11/294,963 US20060251580A1 (en) 2003-06-06 2005-12-06 Lectin conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10325752A DE10325752A1 (de) 2003-06-06 2003-06-06 Lektin-Konjugate
DE10325752.7 2003-06-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/294,963 Continuation US20060251580A1 (en) 2003-06-06 2005-12-06 Lectin conjugates

Publications (2)

Publication Number Publication Date
WO2004108747A2 WO2004108747A2 (de) 2004-12-16
WO2004108747A3 true WO2004108747A3 (de) 2005-03-24

Family

ID=33482652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006141 WO2004108747A2 (de) 2003-06-06 2004-06-07 Lektin-konjugate

Country Status (5)

Country Link
US (1) US20060251580A1 (de)
EP (1) EP1635879A2 (de)
JP (1) JP2006527182A (de)
DE (1) DE10325752A1 (de)
WO (1) WO2004108747A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10329087B4 (de) * 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigenhaltige Mikrosphären zur Allergietherapie
US20090208409A1 (en) * 2008-02-15 2009-08-20 The Government Of The United States Of America, As Represented By The Secretary, Dhhs Encapsulated nanoparticles for computed tomography imaging
US8178319B2 (en) * 2008-05-08 2012-05-15 Peter Pahlsson Peptides and uses thereof
JP2011079776A (ja) * 2009-10-07 2011-04-21 Doshisha 歯周病予防剤
JP5959440B2 (ja) 2010-01-19 2016-08-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 病原体の検出および治療のための改変オプソニン
WO2012113733A1 (de) * 2011-02-21 2012-08-30 Johann Wolfgang Goethe-Universität, Frankfurt Am Main Nanopartikel als mrt-kontrastmittel zur diagnostik des hepatozellulären karzinoms
EP2952210A3 (de) * 2011-04-07 2016-03-16 Emory University Zusammensetzungen mit saccharidbindenden teilen und verfahren zur gezielten therapie
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
AU2013225823A1 (en) 2012-02-29 2014-09-18 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
EP2976642A4 (de) 2013-03-15 2016-09-21 Harvard College Verfahren und zusammensetzungen zur verbesserung der erkennung und/oder aufnahme einer zieleinheit
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
WO2015072786A1 (ko) * 2013-11-18 2015-05-21 한국생명공학연구원 헬리시움 에리나슘 버섯 유래의 시알산 결합 특이적인 렉틴
JP6356256B2 (ja) 2013-11-18 2018-07-11 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ シアル酸結合に特異的なヤマブシタケ由来のレクチン
GB201411393D0 (en) * 2014-06-26 2014-08-13 Isis Innovation Agents and methods for determining colorectal cancer status
EP3331549B1 (de) 2015-08-06 2020-12-23 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
US10507252B2 (en) 2016-03-17 2019-12-17 Paul C. Lee Nanoparticle probes and methods of making and use thereof
US10507253B2 (en) 2016-03-17 2019-12-17 Paul C. Lee Nanoparticle probes and methods of making and use thereof
CN107315056B (zh) * 2017-07-08 2019-09-24 万舒（北京）医药科技有限公司 测定大鼠血浆生物样品中的DTPA-Ca的方法
CN107340343B (zh) * 2017-07-08 2019-08-23 万舒（北京）医药科技有限公司 测定人血浆生物样品中的DTPA-Zn的方法
CA3229988A1 (en) 2021-10-01 2023-04-06 Dhananjay Sathe Recombinant glycan binding proteins and its use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005203A1 (en) * 1992-09-04 1994-03-17 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
WO1996010359A1 (en) * 1994-10-03 1996-04-11 The Trustees Of The University Of Pennsylvania Chelate complex with high conspicuity for magnetic resonance imaging
DE10013849A1 (de) * 1999-09-08 2001-03-15 Diagnostikforschung Inst L-Selectin-Kontrastmittel
US6562318B1 (en) * 1990-09-14 2003-05-13 Syngenix Limited Particular agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074643A (en) * 1993-09-09 2000-06-13 Cli Oncology, Inc. Site-directed chemotherapy of metastases
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
AU8657098A (en) * 1997-05-30 1998-12-30 Arch Development Corporation P-selectin translocation to vascular epithelial lumen by ionizing radiation
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
CZ2002343A3 (cs) * 1999-07-29 2002-08-14 Epix Medical, Inc. Cílená multimerní zobrazovací činidla s multilokální vazebnou schopností
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) * 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562318B1 (en) * 1990-09-14 2003-05-13 Syngenix Limited Particular agents
WO1994005203A1 (en) * 1992-09-04 1994-03-17 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
WO1996010359A1 (en) * 1994-10-03 1996-04-11 The Trustees Of The University Of Pennsylvania Chelate complex with high conspicuity for magnetic resonance imaging
DE10013849A1 (de) * 1999-09-08 2001-03-15 Diagnostikforschung Inst L-Selectin-Kontrastmittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOJIMA S ET AL: "COMPARISONS OF LABELING EFFICIENCY, BIOLOGICAL ACTIVITY AND BIODISTRIBUTION AMONG 125I-, 67GA-DTPA- AND 67GA-DFO-LECTINS", EUROPEAN JOURNAL OF NUCLEAR MEDICINE, BERLIN, DE, vol. 13, no. 7, 1987, pages 366 - 370, XP002054498, ISSN: 0340-6997 *
LEE REIKO T ET AL: "A derivative of diethylenetriaminepentaacetic acid for europium labeling of proteins", BIOCONJUGATE CHEMISTRY, vol. 12, no. 6, November 2001 (2001-11-01), pages 845 - 849, XP002313021, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
US20060251580A1 (en) 2006-11-09
JP2006527182A (ja) 2006-11-30
WO2004108747A2 (de) 2004-12-16
EP1635879A2 (de) 2006-03-22
DE10325752A1 (de) 2004-12-30

Similar Documents

Publication Publication Date Title
WO2004108747A3 (de) Lektin-konjugate
HK1246200A1 (zh) β-葡糖苷酸藥物連接子綴合物
AU2003253048A1 (en) Tubulysin conjugates
WO2006132670A3 (en) Auristatins having an aminobenzoic acid unit at the n terminus
EP2292248A3 (de) Antiangiogene Verbindungen
WO2007024536A3 (en) Process for preparing maytansinoid antibody conjugates
PL2090323T3 (pl) Koniugaty hiperrozgałęzionych polimerów przez nieenzymatyczne odszczepialne łączniki
WO2010033240A3 (en) Carbohydrate-based drug delivery polymers and conjugates thereof
WO2008082669A3 (en) Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
AU2003288467A1 (en) Immunoconjugates with an intracellularly-cleavable linkage
IL209494A0 (en) Insulin-oligomer conjugates, formulations and uses thereof
AU2003298993A1 (en) Polymer-linker-drug conjugates for targeted drug delivery
AU2003217576A1 (en) Molecular sensors by competitive activation
AU2003302235A1 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
EP1846737A4 (de) Ultraschallstrahlenformungsvorrichtung
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
AU2003901897A0 (en) Conjugate
BR0103563B1 (pt) montagem de braço oscilante.
PL376481A1 (en) Conjugated hydroxyalkyl starch allergen compounds
WO2007079404A3 (en) Drug-polymer conjugates
IL178791A (en) 104SC Monoclonal Antibody and its History Specifically Related to CialilTrausil Carbohydrate as a Potential Antimicrobial Treatment
USD542867S1 (en) Electromechanical exercise apparatus
AU2002306068A1 (en) Biodegradable, environmentally-friendly pants diaper
AU2003217782A1 (en) Dna-binding polyamide drug conjugates
WO2007050789A3 (en) Glycosyl-oligonucleotide conjugates and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006508288

Country of ref document: JP

Ref document number: 11294963

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004739672

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004739672

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11294963

Country of ref document: US